Life Science News

GenSpera, Inc. (OTCQB:GNSZ) reported the enrolment of the first patient in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

GenSpera, Inc. (OTCMKTS:GNSZ) reported the enrolment of the first patient in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

As quoted in the press release:

The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.

Click here to read the GenSpera Inc. (OTCQB:GNSZ) press release

Featured

MARKETS

Markets
TSX20197.61+15.69
TSXV702.09-3.49
DOW31261.90+8.77
S&P 5003901.36+0.57
NASD11354.62-33.88
ASX7145.60+81.10

COMMODITIES

Commodities
Gold1846.530.00
Silver21.750.00
Copper4.30+0.02
Palladium1968.650.00
Platinum957.670.00
Oil110.35-1.86
Heating Oil3.62-0.05
Natural Gas8.06-0.25

DOWNLOAD FREE REPORTS

×